Synthesis, structure, and antimycobacterial activity of 6-[1(3H)-isobenzofuranylidenemethyl]purines and analogs. Bioorg Med Chem

ARTICLE *in* BIOORGANIC & MEDICINAL CHEMISTRY · SEPTEMBER 2009

Impact Factor: 2.79 · DOI: 10.1016/j.bmc.2009.08.012 · Source: PubMed

3 AUTHORS, INCLUDING:

Vebjørn Bakken
University of Oslo
30 PUBLICATIONS **2,138** CITATIONS

SEE PROFILE

Bioorganic & Medicinal Chemistry 17 (2009) 6512–6516

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc

Synthesis, structure, and antimycobacterial activity of 6-[1(3*H*)-isobenzofuranylidenemethyl]purines and analogs

Morten Brændvang, Vebjørn Bakken, Lise-Lotte Gundersen *

Department of Chemistry, University of Oslo, PO Box 1033, Blindern, N-0315 Oslo, Norway

ARTICLE INFO

Article history:
Received 7 April 2009
Revised 4 August 2009
Accepted 6 August 2009
Available online 12 August 2009

Keywords:
Purines
Cross-couplings
Antimycobacterials
X-ray
Ab initio calculations

ABSTRACT

6-Benzofuryl-, styryl, benzyl, and furfurylpurines as well as 6-[1(3*H*)-isobenzofuranylidenemethyl]purines have been synthesized and their activities against *Mycobacterium tuberculosis* (*Mtb*) determined. Several compounds displayed profound antimycobacterial activity in combination with low toxicity towards mammalian cells. NMR and X-ray crystallography were employed to determine the detailed structures and the results were supported by quantum chemical calculations.

1. Introduction

Tuberculosis (TB) still claims ca. two-million deaths per year world-wide and resistance to existing drugs is a growing problem.[1] We have previously reported selective antibacterial activity against *Mycobacterium tuberculosis* (*Mtb*) for certain 9-benzylpurines.[2] Fig. 1 shows examples of purines with profound antimycobacterial activity as well as a summary of SAR knowledge. Previous results have led us to believe that an aryl group in the purine 6-position is a requirement for significant antimycobacterial effect,[2a] and among the 6-aryl- and 6-heteroarylpurines examined, especially high activities are found for 6-(2-furyl)purines,[2e] for instance compounds **1a**–**1d** (Fig. 1). The more bulky 6-(benzofur-2-yl)purine **2a** is less active than the corresponding furylpurine **1a**.[2d] However, we recently found MIC values for antimycobacterial activity of 6-[1(3*H*)-isobenzofuranylidenemethyl]purines **3a** and **4a** only one titer step higher than 6-furylpurine **1a**.[3] Since we have shown that compound **4a** easily isomerizes into the *Z*-isomer **3a**,[3] it may be that compound **4a** also isomerizes into compound **3a** in the antimycobacterial assay.

The profound, and somewhat unexpected, effect on *Mtb* growth found for the *Z*-6-[1(3*H*)-isobenzofuranylidenemethyl]purine **3a**, prompted us to synthesize and determine antimycobacterial activity for the related compound **3b** (Fig. 1) where the substitution pattern elsewhere in the molecule is optimized according to our current SAR knowledge, as well as the optimized 6-(benzofur-2-yl)purine **2b** (Fig. 1) and the styryl- **5**, benzyl- **6**, and furfurylpurine **7**. The structural relationship between compounds **5**–**7** and the (isobenzofuranylidenemethyl)purine **3b**, is illustrated in Figure 2. It was previously shown that compound **3a** exists only as a (isobenzofuranylidenemethyl)purine, and not as an aromatic, but quinoid, benzo[*c*]furylmethylpurine.[3] On the other hand, the simple furyl derivative **7**, may exist as tautomer **7b** rather than **7a**. Hence, we included a structural study of the synthesized compounds employing NMR, X-ray, and quantum chemical calculations in order to reveal their detailed structures and broaden our SAR knowledge.

2. Synthesis

Z-6-[1(3*H*)-Isobenzofuranylidenemethyl]purine **3b** was synthesized essentially as reported for the preparation of compound **3a** before.[3] When the dichloropurine **8** was reacted with the alkyne **9** under Sonogashira coupling conditions, cyclization took place to give mainly the *E*-isomer **4b**. The mixture of isomers was treated with TFA to give the pure *Z*-6-[1(3*H*)-isobenzofuranylidenemethyl]purine **3b** (Scheme 1).

The other target molecules, **2b** and **5**–**7**, were available by regioselective Stille- or Negishi-coupling on the dichloropurine **8** (Scheme 2, Table 1) a synthetic strategy employed by us in the synthesis of several 6-substituted purines.[1,4] Furfuryl halides are regarded as unstable and difficult to utilize for synthetic purposes.[5] However, we found that the desired furfurylzinc chloride could be generated from furfuryl chloride and Rieke zinc following the protocol previously used for generation of benzylzinc chloride.[6]

* Corresponding author. Tel.: +47 22857019; fax: +47 22855507.
E-mail address: l.l.gundersen@kjemi.uio.no (L.-L. Gundersen).

0968-0896/$ - see front matter © 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2009.08.012



Figure 1. Structures of antimycobacterial purines and previously reported MIC values,[2a,d,e,3] summary of SAR for antimycobacterial 9-benzylpurines, and target molecules in the study.

This constitutes the first formation and synthetic application of a furfurylmetal reagent carrying no stabilizing groups on the furyl ring.

3. Structure

In line with our previous observations on compound **3a**,[3] no quinoid benzo[*c*]furylmethylpurine tautomer could be detected in the ^{1}H NMR spectrum of the *Z*-6-[1(3*H*)-isobenzofuranylidenemethyl]purine **3b** or the isomer **4b**. On the other hand, ^{1}H NMR revealed that compound **7** was present only as the furfurylpurine **7b**. Electronic structure calculations supported these findings (see Supplementary data). The furfurylpurine **7** also crystallized as the **7b** tautomer (Fig. 3). The benzyl group in crystalline compound **7b** is oriented quite different from what is previously found by X-ray crystallography for the benzylic substituent in the 6-furylpurine **1d**[7] and related structures,[8] for further discussions, see Supplementary data.

4. Antimycobacterial activity

The novel purine derivatives **2b**, **3b**, **5**, **6**, and **7b** were screened for antibacterial activity against *M. tuberculosis* $H_{37}Rv$ in vitro and the IC_{90} and IC_{50} values are presented in Table 2 together with comparable data for the compounds **1d** and **3a** synthesized earlier. Previously determined MIC values (*Mtb*) for compounds **1a**–**1d**, **2a**, **3a**, and **4a** are displayed in Figure 1.

Both the 6-furyl- **1d** and 6-benzofurylpurine **2b** were found to be highly potent inhibitors of *Mtb* (IC_{90} <0.20 μg/mL, <0.6 μM). As expected, both (isobenzofuranylidenemethyl)purines **3a** and **3b** also displayed considerable growth inhibition (IC_{90} 3–5 μg/mL, 8–12 μM). However, the furfurylpurine **7b** was essentially inactive (IC_{90} >100 μg/mL) whereas the benzyl- **6** and styrylpurine **5** were only slightly weaker inhibitors (IC_{90} 6–11 μg/mL, 16–30 μM) compared to the (isobenzofuranylidenemethyl)purines **3**. None of the novel compounds described herein could compete with 6-furyl- **1d** or 6-benzofurylpurine **2b** where the aryl substituent is connected



Figure 2. Target molecules **5–7** and their structural relationship with target molecule **3b**.



Scheme 1. Reagents and conditions: (a) $(Ph_3P)_2PdCl_2$, CuI, $(i\text{-}Pr)_2NH$, DMF, 60 °C; (b) TFA, CH_2Cl_2.



Scheme 2. Reagents and conditions: (a) R-Met, Pd-cat, 50 °C, for more details, see Table 1.

Table 1
Reaction conditions applied in synthesis of compounds **5**–**7**

–Met	Pd-catalyst	Solvent	Time (h)	Yield (%)
$-SnBu_3$	$[(2\text{-Furyl})_3P]_4Pd$	DMF	8	78, **2b**
$-SnBu_3$	$[(2\text{-Furyl})_3P]_4Pd$	DMF	7	77, **5**
–ZnCl	$(Ph_3P)_4Pd$	THF	5	69, **6**
–ZnCl	$(Ph_3P)_4Pd$	THF	3	59, **7**

directly to C-6 in the purine, with respect to inhibition of *Mtb*. However, and in contrast to our previous believe (Fig. 1),[2] also other substituents (i.e., styryl- or isobenzofuranylidenemethyl-) in the 6-position may result in purines with a considerable antimycobacterial activity. The compounds displaying IC_{90} values against *Mtb* lower than 10 μg/mL were also screened for toxicity towards mammalian cells (VERO cells, Table 2). All compounds examined, except **3a**, showed IC_{50} against VERO cells >40 μg/mL. We have previously reported that compound **1c** (Fig. 1) showed virtually no cross resistance against a panel of drug-resistant *Mtb* strains.[2b] We assume that the closely related structures reported herein act by the same, currently unknown, mechanism of action as purine **1c**, so we have reasons to believe that cross resistance will not be an issue for the novel compounds described herein.

5. Experimental

The ^1H NMR spectra were recorded at 300 MHz with a Bruker Avance DPX 300 instrument, and the ^1H decoupled ^{13}C NMR spectra were recorded 75 MHz using the same instrument. Mass spectra under electron impact conditions (EI) were recorded at 70 eV ionizing voltage with a VG Prospec instrument, and are presented as *m*/*z* (% rel. int.). Elemental analyses were performed by Ilse Beetz Mikroanalytisches Laboratorium, Kronach, Germany. Melting points were determined with a C. Reichert melting point apparatus or a Büchi Melting Point B-545 apparatus and are uncorrected. DMF was distilled from BaO and stored over 4 Å mol. sieve, dichloromethane was distilled from CaH_2, and THF from Na/benzophenone. Antimycobacterial activity was determined as previously reported.[2] The following compounds were prepared according to literature procedures: 2-chloro-6-(2-furyl)-9-(4-methoxyphenylmethyl)-9*H*-purine **1d**,[2d] (*Z*)-9-benzyl-6-[isobenzofuran-1(3*H*)-ylidenemethyl]-9*H*-purine **3a**,[2] 2,6-dichloro-9-(4-methoxyphenylmethyl)-9*H*-purine **8**,[2d] (*E*)-tributyl(phenylethenyl)stannane,[9] tributyl(benzo[*b*]fur-2-yl)stannane,[10] and furfuryl chloride.[11] Benzylzinc chloride was generated from benzyl chloride and Rieke zinc[12] according to a published procedure[6] and the concentration of the solution was determined by hydrolysis and iodolysis.[13] Furfurylzinc chloride was generated from furfuryl chloride following the same protocol.

5.1. X-ray crystallographic analysis for compound 7b

Crystals of **7b** suitable for X-ray crystallography were obtained from benzene solution at +4 °C. X-ray data were collected on a Siemens SMART CCD diffractometer[14] using graphite monochromated Mo Kα radiation (λ = 0.71073 Å). Data collection method: ω-scan, step 0.3°, crystal to detector distance 5 cm. Data reduction and cell determination were carried out with the SAINT and XPREP programs. Absorption corrections were applied by the use of the SADABS program.[15] The structure was determined and refined using the SHELX program package.[16] The non-hydrogen atoms were refined with isotropic thermal parameters; H atoms were positioned geometrically and allowed to ride and rotate (for the CH_3 group) on their carrier atoms, with C–H bond lengths of 0.95 (aromatic C–H), 0.99 (CH_2) or 0.98 Å (CH_3) and with $U_{iso}(H) = 1.2U_{eq}(C)$ for CH_2 and aromatic C–H or $1.5U_{eq}(C)$ for CH_3. Crystal structure data for **7b** are available from the Cambridge Crystallographic Data Center, CCDC no. 643827.



Figure 3. X-ray structure of compound **7b**, the gas-phase equilibrium structure of compound **7b**, and X-ray structure of compound **1d**.[7]

Table 2
Activity against *M. tuberculosis* for purines **1d, 2b**, **3a**, **3b**, **5**, **6**, and **7b** as well as cytotoxicity against VERO cells for selected compounds[a]

Compound	IC_{90} *M. tuberculosis* $H_{37}Rv$ (μg/mL), μM values in brackets[b]	IC_{50} *M. tuberculosis* $H_{37}Rv$ (μg/mL), μM values in brackets[b]	IC_{50} VERO cells (μg/mL)[c]
1d	<0.20 (<0.59)	<0.20 (<0.59)	>40
2b	<0.20 (<0.51)	<0.20 (<0.51)	>40
3a	2.7 (7.9)	1.5 (4.3)	17
3b	4.9 (12)	<0.20 (<0.48)	>40
5	6.1 (16)	3.0 (8.0)	>40
6	11 (30)	7.4 (20)	n.d.
7b	>100 (>280)	>100 (>280)	n.d.

[a] Structures of compounds are shown in Schemes 1 and 2.
[b] IC_{90} amicain 0.13 μg/mL (0.22 μM) and IC_{50} amicain 0.07 μg/mL (0.12 μM).
[c] EC_{50} hyamine 0.01 μg/mL.

5.2. Crystal data for $C_{18}H_{15}ClN_4O_2$ 7b

M = 354.79, monoclinic, $P2(1)/n$ a = 4.5528 (6) Å, b = 18.867(3) Å, c = 18.955(3) Å, β = 96.486(2)°, V = 1617.8(4) Å^3, Z = 4, Dx = 1.457 Mg m^{-3}, μ = 0.26 mm^{-1}, T = 105(2) K, measured 16,774 reflections in 2θ range 6.2–60.6°, R_{int} = 0.032. To 128 parameters refined against 4518 F^2, R = 0.0333 for 3293 $I_o > 2\sigma(I_o)$ and 0.0553 for all data.

5.3. Antimycobacterial data

The purines were screened for antimycobacterial activities essentially as described before.[2,17] Compounds were tested in 10 twofold dilutions, from 100 to 0.19 μg/mL, against *M. tuberculosis* $H_{37}Rv$ (ATCC 27294) in BACTEC 12B medium using the Microplate Alamar Blue Assay (MABA). The IC_{90} and IC_{50} values are determined from the dose–response curve as the IC_{90} using the curve fitting program XLFIT, formula 205.

5.4. Activity against VERO cells

The compounds were screened for mammalian cell cytotoxicity to VERO cells essentially as described before;[2] after 72 h exposure, viability is assessed using the CellTiter 96® Non-Radioactive Cell Proliferation Assay (MTT) reagent from Promega. Cytotoxicity is determined from the dose–response curve as the EC_{50} using the curve fitting program XLFIT, formula 205.

5.5. 6-(Benzofuran-2-yl)-2-chloro-9-(4-methoxyphenylmethyl)-9*H*-purine (2b)

A mixture of tris(dibenzylideneacetone)dipalladium, Pd_2dba_3 (28 mg, 0.030 mmol), and tri(2-furyl)phosphine (51 mg, 0.22 mmol) in dry DMF (4 mL) was stirred at ambient temperature for 5 min, before a solution of 2,6-dichloro-9-(4-methoxyphenylmethyl)-9*H*-purine **8** (309 mg, 1.0 mmol) in DMF (4 mL) was added. After an additional 5 min, tributyl(benzo[*b*]fur-2-yl)stannane (575 mg, ca. 1.20 mmol, ca. 85% pure) was introduced, the resulting mixture stirred at 50 °C for 8 h and evaporated in vacuo. A satd solution of potassium fluoride in methanol (40 mL) was added to the residue, the mixture was stirred over night and evaporated in vacuo together with a small amount of silica gel. The residue was added on top of a silica gel column, and the product purified by flash chromatography eluting with CH_2Cl_2–acetone (29:1), followed by CH_2Cl_2–acetone (19:1); yield 303 mg (78%), mp 189 °C, colorless crystals. ^{1}H NMR (300 MHz, $CDCl_3$) δ = 3.75 (s, 3H, OCH_3), 5.32 (s, 2H, NCH_2), 6.87 (d, J = 8.7 Hz, 2H, Ar), 7.24–7.30 (m, 3H, Ar and benzofuryl), 7.38–7.43 (m, 1H, benzofuryl), 7.67–7.70 (m, 2H, benzofuryl), 8.02 (s, 1H, 8-H) and 8.28 (s, 1H, 3-H in benzofuryl) ppm. ^{13}C NMR (75 MHz, $CDCl_3$) δ = 47.1 (NCH_2), 55.3 (OCH_3), 112.4 (CH in benzofuryl), 114.6 (CH in Ar), 115.2 (CH in benzofuryl), 122.4 (CH in benzofuryl), 123.6 (CH in benzofuryl), 126.4 (C-1 in Ar), 127.2 (CH in benzofuryl), 128.1 (C in benzofuryl), 128.4 (C-5), 129.6 (CH in Ar), 145.1 (C-8), 147.6 (C-6/C-2), 149.7 (C-2 in benzofuryl), 153.7 (C-4), 154.5 (C-2/C-6), 156.0 (C in benzofuryl) and 159.9 (C-4 in Ar) ppm. MS (EI): *m/z* (%): 392/390 (15/42) [M]$^+$, 234 (1), 195 (1), 181 (2), 122 (9), 121 (100). HRMS (EI): calcd for $C_{21}H_{15}ClN_4O_2$ 390.0884, found 390.0886. $C_{21}H_{15}ClN_4O_2$ (390.8): C, 64.54; H, 3.87; N, 14.34. Found: C, 64.50; H, 3.93; N, 14.20.

5.6. 2-Chloro-6-[(*Z*)-1(3*H*)-isobenzofuranylidenemethyl]-9-(methoxyphenylmethyl)-9*H*-purine (3b)

2,6-Dichloro-9-(4-methoxyphenylmethyl)-9*H*-purine **8** (155 mg, 0.50 mmol) was added to a stirring solution of CuI (9.5 mg, 0.050 mmol), bis(triphenylphosphine)palladium(II) chloride (18 mg, 0.025 mmol), and dry diisopropylamine (420 μL, 3.00 mmol) in dry DMF (2.5 mL) under N_2. The solution was heated to 60 °C before 2-ethynylbenzenemethanol **9** (79 mg, 0.60 mmol) dissolved in DMF (1 mL) was added dropwise over 1 h. After stirring for additional 4 h at 60 °C, the reaction mixture evaporated in vacuo with a small amount of silica. The residue was added on top of a silica gel column, and the product, as a ca. 7:3 *E*/*Z* mixture was isolated by flash chromatography eluting with CH_2Cl_2–acetone (19:1) followed by CH_2Cl_2–acetone (9:1). The isomeric mixture was dissolved in CH_2Cl_2 (30 mL) and trifluoroacetic acid (74 μL, 0.96 mmol) was added. After stirring for 1 h at ambient temperature the reaction mixture was washed with satd aq $NaHCO_3$ (2 × 20 mL), water (20 mL), brine (20 mL), dried ($MgSO_4$) and evaporated in vacuo. The product was purified by flash chromatography on silica gel eluting with CH_2Cl_2–acetone (9:1); yield 101 mg (50%), pale yellow crystals. ^{1}H NMR (300 MHz, $CDCl_3$) δ = 3.76 (s, 3H, OCH_3), 5.28 (s, 2H, NCH_2), 5.71 (s, 2H, OCH_2), 6.72 (s, 1H, =CH), 6.87 (d, J = 8.7 Hz, 2 H, Ar), 7.25 (d, J = 8.7 Hz, 2H, Ar), 7.40–7.48 (m, 3H, Ar′), 7.79–7.82 (m, 1H, Ar′) and 7.84 (s, 1H, 8-H) ppm. ^{13}C NMR (75 MHz, $CDCl_3$) δ = 46.8 (NCH_2), 55.3 (OCH_3), 77.2 (OCH_2), 88.6 (=CH), 114.5 (CH in Ar), 121.3 (CH in Ar′), 121.8 (CH in Ar′), 126.9 (C-1 in Ar), 128.5 (CH in Ar′), 129.0 (C-5), 129.6 (CH in Ar), 131.1 (CH in Ar′), 133.9 (C in Ar′), 141.5 (C in Ar′), 142.7 (C-8), 152.1 (C-4), 154.6 (C-2/C-6), 156.2 (C-6/C-2), 159.8 (C-4 in Ar) and 165.7 (=C) ppm. MS (EI): *m/z* (%): 406/404 (9/25) [M]$^+$, 285 (3), 284 (2), 283 (8), 140 (2), 121 (100). HRMS (EI): calcd for $C_{22}H_{17}ClN_4O_2$ 404.1040, found 404.1030. $C_{22}H_{17}ClN_4O_2$ (404.9): C, 65.27; H, 4.23; N, 13.84. Found: C, 64.94; H, 4.16; N, 13.81.

5.7. (*E*)-2-Chloro-9-(4-methoxybenzyl)-6-(2-phenylethenyl)-9*H*-purine (5)

The product was formed by Stille coupling between 2,6-dichloro-9-(4-methoxyphenylmethyl)-9*H*-purine **8** (309 mg, 1.0 mmol) and (*E*)-tributyl(phenylethenyl)stannane (1.12 g, 1.20 mmol, ca. 42% purity) as described for compound **3b** above. The reaction time was 7 h, and the product purified by flash chromatography on silica gel eluting with CH_2Cl_2–acetone (29:1), followed by CH_2Cl_2–acetone (19:1) and finally CH_2Cl_2–acetone (9:1); yield 292 mg (77%), colorless foam. ^{1}H NMR (300 MHz, $CDCl_3$) δ = 3.75 (s, 3H, OCH_3), 5.30 (s, 2H, NCH_2), 6.88 (d, J = 8.8 Hz, 2H, Ar), 7.26 (d, J = 8.8 Hz, 2H, Ar), 7.32–7.42 (m, 3H, Ph), 7.59 (d, J = 16.1 Hz, 1H, CH=), 7.66–7.69 (m, 2H, Ph), 7.94 (s, 1H, 8-H) and 8.42 (d, J = 16.1 Hz, 1H, CH=) ppm. ^{13}C NMR (75 MHz, $CDCl_3$) δ = 47.0 (NCH_2), 55.3 (OCH_3), 114.5 (CH in Ar), 121.4 (CH=), 126.6 (C-1 in Ar), 128.1 (CH in Ph), 128.8 (CH in Ph), 129.6 (CH in Ar), 129.8 (CH in Ph), 130.0 (C-5), 135.7 (C-1 in Ph), 141.7 (CH=), 144.3 (C-8), 153.4 (C-4), 154.3 (C-2), 155.8 (C-6) and 159.9 (C-4 in Ar) ppm. MS (EI): *m/z* (%): 378/376 (13/36) [M]$^+$, 257 (1), 255 (4), 122 (9), 121 (100). HRMS (EI): calcd for $C_{21}H_{17}ClN_4O$ 376.1091, found 376.1093. $C_{21}H_{17}ClN_4O$ (376.8): C, 66.93; H, 4.55; N, 14.87. Found: C, 66.76; H, 4.46; N, 14.71.

5.8. 6-Benzyl-2-chloro-9-(4-methoxyphenylmethyl)-9*H*-purine (6)

2,6-Dichloro-9-(4-methoxyphenylmethyl)-9*H*-purine **8** (309 mg, 1.0 mmol) was added to a solution of tetrakis(triphenylphosphine)palladium(0) [generated in situ from tris(diphenylmethylideneacetone)dipalladium chloroform adduct (23 mg, 0.025 mmol) and triphenylphosphine (53 mg, 0.20 mmol)] in dry THF (4 mL) at ambient temperature under N_2. After 10 min, a solution of benzylzinc chloride (1.83 mL, 1.52 mmol, 0.83 M) in THF was added and the mixture stirred at 50 °C for 5 h. Satd aq NH_4Cl (10 mL) was added and the resulting mixture was extracted with EtOAc (4 × 25 mL). The combined organic extracts were washed with brine (2 × 20 mL), dried ($MgSO_4$), and evaporated in vacuo with a small amount on silica. The residue was added on top of a silica gel column, and the product purified by flash chromatography eluting with CH_2Cl_2–acetone (29:1), followed by CH_2Cl_2–acetone (19:1) and finally CH_2Cl_2–acetone (9:1); yield 250 mg (69%), colorless oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ = 3.74 (s, 3H, OCH_3), 4.43 (CH_2), 5.25 (s, 2H, NCH_2), 6.85 (d, J = 8.7 Hz, 2H, Ar), 7.11–7.27 (m, 2H, Ar and 3H, Ph), 7.45–7.48 (m, 2H, Ph) and 7.92 (s, 1H, 8-H) ppm. ^{13}C NMR (75 MHz, $CDCl_3$) δ = 39.5 (CH_2), 47.0 (NCH_2), 55.3 (OCH_3), 114.5 (CH in Ar), 126.4 (C-1 in Ar), 126.7 (CH in Ph), 128.5 (CH in Ph), 129.3 (CH in Ph), 129.6 (CH in Ar), 131.7 (C-5), 137.0 (C-1 in Ph), 144.4 (C-8), 152.8 (C-4), 154.1 (C-2), 159.9 (C-4 in Ar) and 162.8 (C-6) ppm. MS (EI): *m/z* (%): 366/364 (24/60) $[M]^+$, 245 (9), 243 (27), 207 (2), 180 (3), 153 (2), 121 (100). HRMS (EI): calcd for $C_{20}H_{17}ClN_4O$ 364.1091, found 364.1090. $C_{20}H_{17}ClN_4O$ (363.8): C, 65.84; H, 4.70; N, 15.36. Found: C, 65.83; H, 4.84; N, 15.26.

5.9. 2-Chloro-6-(furan-2-ylmethyl)-9-(4-methoxyphenylmethyl)-9*H*-purine (7b)

The product was formed by Negishi coupling between 2,6-dichloro-9-(4-methoxyphenylmethyl)-9*H*-purine **8** (309 mg, 1.0 mmol) and furfurylzinc chloride (3.9 mL, 1.60 mmol, 0.41 M) as described for compound **6** above. The reaction time was 3 h, and the product purified by flash chromatography on silica gel eluting with CH_2Cl_2–acetone (29:1), followed by CH_2Cl_2–acetone (19:1) and finally CH_2Cl_2–acetone (9:1); yield 208 mg (59%), mp 135 °C, colorless crystals. ^{1}H NMR (300 MHz, $CDCl_3$) δ = 3.74 (s, 3H, OCH_3), 4.46 (s, 2H, CH_2), 5.27 (s, 2H, NCH_2), 6.22 (dd, J = 3.2 and 0.7 Hz, 1H, 3-H in furyl), 6.25 (dd, J = 3.2 and 1.9 Hz, 1H, 4-H in furyl), 6.85 (d, J = 8.7 Hz, 2H, Ar), 7.25 (d, J = 8.7 Hz, 2H, Ar), 7.28 (dd, J = 1.8 and 0.8 Hz, 1H, 5-H in furyl) and 7.94 (s, 1H, 8-H) ppm. ^{13}C NMR (75 MHz, $CDCl_3$) δ = 32.2 (CH_2), 47.0 (NCH_2), 55.3 (OCH_3), 107.6 (C-3 in furyl), 110.5 (C-4 in furyl), 114.5 (CH in Ar), 126.4 (C-1 in Ar), 129.6 (CH in Ar), 131.7 (C-5), 141.9 (C-5 in furyl), 144.7 (C-8), 149.9 (C-2 in furyl), 152.9 (C-4), 154.1 (C-2), 159.8 (C-6) and 159.9 (C-4 in Ar) ppm. MS (EI): *m/z* (%): 356/354 (15/43) $[M]^+$, 121 (100), 91 (3), 78 (5), 77 (5). HRMS (EI): calcd for $C_{18}H_{15}ClN_4O_2$ 354.0884, found 354.0873. $C_{18}H_{15}ClN_4O_2$ (354.8): C, 60.94; H, 4.26; N, 15.79. Found: C, 60.92; H, 4.28; N, 15.71.

Acknowledgments

Antimycobacterial data were provided by the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) through a research and development contract with the US National Institute of Allergy and Infectious Diseases. We are grateful for all help provided by Dr. Cecil Kwong and co-workers. This work has received support through a grant of computer time from the Research Council of Norway (Grant No. NN1118K). NFR is also greatly acknowledged for partial financing of the Bruker Avance instrument used in this study. We thank Dr. Osamu Sekiguchi, Department of Chemistry, University of Oslo for the single-crystal data collection and initial refinement and Tom Chr. Berg for the synthesis of compound **3a**.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.bmc.2009.08.012.

References and notes

1. See for instance: Bhowruth, V.; Dover, L. G.; Besra, G. S. *Prog. Med. Chem.* **2007**, *45*, 169. and references therein.
2. (a) Bakkestuen, A. K.; Gundersen, L.-L.; Langli, G.; Liu, F.; Nolsøe, J. M. N. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 1207; (b) Gundersen, L.-L.; Nissen-Meyer, J.; Spilsberg, B. *J. Med. Chem.* **2002**, *45*, 1383; (c) Andresen, G.; Gundersen, L.-L.; Nissen-Meyer, J.; Rise, F.; Spilsberg, B. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 567; (d) Bakkestuen, A. K.; Gundersen, L.-L.; Utenova, B. T. *J. Med. Chem.* **2005**, *48*, 2710; (e) Brændvang, M.; Gundersen, L.-L. *Bioorg. Med. Chem.* **2005**, *13*, 6360; (f) Brændvang, M.; Gundersen, L.-L. *Bioorg. Med. Chem.* **2007**, *15*, 7144.
3. Berg, T. C.; Bakken, V.; Gundersen, L.-L.; Petersen, D. *Tetrahedron* **2006**, *62*, 6121.
4. Langli, G.; Gundersen, L.-L.; Rise, F. *Tetrahedron* **1996**, *52*, 5625.
5. Takanishi, K.; Hirokazu, U.; Kuwajima, I. *Tetrahedron Lett.* **1987**, *28*, 2281.
6. Zhu, L.; Wehmeyer, R. M.; Rieke, R. D. *J. Org. Chem.* **1991**, *56*, 1445.
7. (a) Brændvang, M.; Gundesen, L.-L. *Acta. Crystallogr., Sect. C* **2007**, *63*, o274–o276; (b) Brændvang, M.; Gundersen, L.-L. *Acta. Crystallogr., Sect. E* **2007**, *63*, o3036.
8. Mazumdar, P. A.; Das, A. K.; Bakkestuen, A. K.; Gundersen, L.-L.; Bertolasi, V. *Acta. Crystallogr., Sect. E* **2001**, *57*, o1052.
9. Labadie, J. W.; Tueting, D.; Stille, J. K. *J. Org. Chem.* **1983**, *48*, 4634.
10. Liebeskind, L. S.; Wang, J. *J. Org. Chem.* **1993**, *58*, 3550.
11. Chaudhari, S. S.; Akamanchi, K. G. *Synlett* **1999**, 1763.
12. (a) Chen, T.-A.; Wu, X.; Rieke, R. D. *J. Am. Chem. Soc.* **1995**, *117*, 233–244; (b) Rieke, R. D.; Hanson, M. V.; Brown, J. D.; Niu, Q. J. *J. Org. Chem.* **1996**, *61*, 2726.
13. Knochel, P.; Jones, P.; Langer, F. In *Organozinc Reagents: A Practical Approach*; Knochel, P., Jones, P., Eds.; Oxford University Press: Oxford, 1999; p 14.
14. SMART (Version 5.625) and SAINT+ (Version 6.02). Area-Detector Control and Integration Software, Bruker Analytical X-ray Instruments, Madison, WI, 1998.
15. Sheldrick, G. M. SADABS. Program for Empirical Correction of Area Detector Data, University of Göttingen, Germany, 1996.
16. Sheldrick, G. M. SHELXL (release 97-2)—Programs for Crystal Structure Analysis Structure, University of Göttingen, Germany, 1997.
17. Collins, L. A.; Franzblau, S. G. *Antimicrob. Agents Chemother.* **1997**, *41*, 1004.